https://www.selleckchem.com/
Mycobacterium abscessus pulmonary disease (Mabscessus-PD) is challenging to treat because of its resistance to antibiotics. What are the outcomes of treatment-naive patients with Mabscessus-PD treated with inhaled amikacin-containing multidrug regimens? We identified 82 treatment-naive patients with Mabscessus-PD from a prospective observational cohort treated with regimens containing inhaled amikacin with or without clofazimine between March 2015 and June 2018 (ClinicalTrials.gov identifier NCT00970801). During the initial phase, all patients received IV a
Curtir
Comentario
Compartilhar
